Lupin Offloads Kyowa For $525m But Not Exiting Japan

$300m Net From Deal Gives Leeway For Acquisitions, Organic Growth

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Tokyo skyline and Mountain Fuji in Japan
Lupin Selling Japan Subsidiary But Still Committed To The Market • Source: Shutterstock

Lupin Ltd. has finally decided to offload to a local private equity group its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd., that had run into troubled waters on account of increasing competition in the local generics segment and the prospect of government-driven price cuts becoming an annual feature in Japan.

The deal is also indicative of private equity's rising interest in the Japan pharma sector, following on from other major...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business